Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Lutathera is FDA approved as first medicine specifically for pediatric patients with gastro-enteropancreatic neuroendocrine tumors – Novartis

Written by | 27 Apr 2024

Novartis announced that the FDA approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with… read more.

In the drive to deprescribe, heartburn drug study teaches key lessons

Written by | 15 Apr 2024

Whether it’s costs, safety risks or “pill fatigue” they’re trying to reduce, many health systems and clinics have started working on ways to encourage deprescribing of medications that… read more.

University of Maryland, Baltimore researchers call for regulation of direct-to-consumer microbiome tests

Written by | 19 Mar 2024

Scientific research has linked a person’s microbiome to everything from gut and mental health to immunity and predisposition to cancer. This research comes at a time when there… read more.

Innovative gel offers new hope for treating gastrointestinal leaks

Written by | 1 Dec 2023

In a major advancement in medical technology, researchers at the Terasaki Institute for Biomedical Innovation have developed an adhesive gel, offering a revolutionary treatment for gastrointestinal leaks, a… read more.

Genetics links endometriosis and IBS

Written by | 29 Oct 2023

University of Queensland researchers have shown that endometriosis and irritable bowel syndrome (IBS) share genetic risk factors, explaining why patients with one condition may also have the other…. read more.

Skyrizi met all primary and secondary endpoints versus Stelara in head-to-head study in Crohn’s disease – AbbVie

Written by | 16 Sep 2023

AbbVie announced top-line results from the Phase III SEQUENCE clinical trial evaluating risankizumab (Skyrizi, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg… read more.

GI symptoms persist in older female colorectal cancer survivors

Written by | 5 Aug 2023

More than 4 out of 5 older women survivors of colorectal cancer may be experiencing a range of gastrointestinal symptoms many years after being diagnosed and treated, a… read more.

The largest study of its kind shows a need for improvement in esophageal cancer screenings

Written by | 25 Jul 2023

A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett’s esophagus (BE). BE is the only identifiable precursor… read more.

Inflammatory bowel disease linked to increased risk of stroke

Written by | 18 Jun 2023

People with inflammatory bowel disease (IBD) are more likely to have a stroke than people without the disease, according to a study published in the June 14, 2023,… read more.

Boosting survival of a beneficial bacterium in the human gut

Written by | 25 Mar 2023

The microbes that inhabit the gut are critical for human health, and understanding the factors that encourage the growth of beneficial bacterial species — known as “good” bacteria… read more.

Study confirms pancreatic cancer rates rising faster in women than men

Written by | 14 Feb 2023

In a large-scale nationwide study, investigators from Cedars-Sinai Cancer have confirmed that rates of pancreatic cancer are rising – and are rising faster among younger women, particularly Black women, than… read more.

Realtime monitoring with a wearable device reveals IBS-related changes

Written by | 18 Jan 2023

Irritable bowel syndrome (IBS) is a difficult disease to treat, characterized by chronic abdominal pain related to bowel movements, of which there are four types: diarrheal, constipation, mixed,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.